Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives
Inventors
Farand, Julie • Kaplan, Joshua A. • Notte, Gregory • Olen, Casey Lockwood • Sangi, Michael • Sperandio, David
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11136290-B2
Publication Date
2021-10-05
Expiration Date
Abstract
Provided is a compound of Formula (I):wherein the variable groups are defined herein.
Core Innovation
The invention relates to compounds defined by Formula II, Formula III, and Formula IV, including pharmaceutically acceptable salts, stereoisomers, mixtures of stereoisomers, tautomers, and deuterated analogs. The compounds are characterized by Q being S(O)2 or —S(O)2— and by extensive structural definitions using variable substituents, with optional substitution, fusion, and joining provisions.
The structural framework enumerates allowed substituent classes for the variables, including alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, halo, hydroxyl, oxo, cyano, alkoxy, hydroxyalkyl, heteroalkyl, and sulfur-containing groups such as —S(O)0-2R, —S(O)(NH)R, —S(O)(NR)R, and related carbonyl and phosphoryl substituents. Conditional provisos constrain certain substituent choices based on variable combinations such as x+y+z and selected H or methyl assumptions.
The disclosure also includes compounds described as mitochondrial uncoupler drug candidates and as substituted benzamide/sulfonamide derivatives, with example compounds including N-(4-cyanobicyclo[2.2.2]octan-1-yl) benzamide sulfonamides and related bicyclic or heterocyclic substituents. The document further includes pharmaceutical compositions comprising the claimed compounds together with pharmaceutically acceptable carriers or excipients.
Claims Coverage
The provided material contains independent claims directed to Formula II, Formula III, and Formula IV compound families, plus claims selecting a compound from a stated group. Across these claims, the core inventive scope is structural and is carried by the Formula-based scaffolds, the Q substituent fixed to S(O)2 or —S(O)2—, and the extensive substituent-variable definitions and provisos. Three main formula claims and one group-selection claim are represented.
Formula II compound framework
A compound of Formula II, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog, wherein x, y, and z are independently 1, 2, 3, or 4; Q is S(O)2; and R21, R22, R23, R24, R27, R28 and related groups are selected from enumerated substituent sets with optional substitution, fusion, and proviso restrictions.
Formula III compound framework
A compound of Formula III, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog, wherein Q is —S(O)2—; R41 and related substituent variables are selected from enumerated groups; and optional substitution rules and provisos restrict certain selections, including a restriction when both R43 and R47 are H.
Formula IV compound framework
A compound of Formula IV, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog, wherein Q is —S(O)2—; R61 and related substituent variables are selected from enumerated groups; and optional substitution rules and joining or fusion relationships constrain allowed selections.
Selected-group compound coverage
A compound selected from the group consisting of the stated group, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, tautomer, or deuterated analog thereof.
The claim coverage is primarily structural, defining compound families by Formula II, Formula III, and Formula IV with Q fixed to S(O)2 or —S(O)2— and with extensive enumerated substituent-variable frameworks and conditional provisos. Additional scope is provided by claims directed to compounds selected from a stated group while expressly including pharmaceutically acceptable salts and specified chemical variants.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Functional potency profiling of disclosed compounds in a PC-3 oxygen consumption rate assay, including EC50 values for PC3 OCR at 3 minutes.
Therapeutic context for mitochondrial uncoupler drug candidates in NAFLD, NASH, ASH, and lipodystrophy.
Interested in licensing this patent?